These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 32981045)

  • 1. Evaluation of clinical performance when intrauterine devices are inserted by different categories of healthcare professional.
    Laporte M; Becerra A; Castro L; Veiga N; Espejo-Arce X; Bahamondes L
    Int J Gynaecol Obstet; 2021 Feb; 152(2):196-201. PubMed ID: 32981045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of levonorgestrel 52 mg intrauterine system compared to copper intrauterine device: a population-based cohort study.
    Bosco-Lévy P; Gouverneur A; Langlade C; Miremont G; Pariente A
    Contraception; 2019 Jun; 99(6):345-349. PubMed ID: 30871933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Menstrual characteristics and ultrasonographic uterine cavity measurements predict bleeding and pain in nulligravid women using intrauterine contraception.
    Kaislasuo J; Heikinheimo O; Lähteenmäki P; Suhonen S
    Hum Reprod; 2015 Jul; 30(7):1580-8. PubMed ID: 25990577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
    Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
    J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrauterine device continuation rates and reasons for discontinuation in a Central European clinic with a high standard of care and ultrasound follow-up: a retrospective cohort study.
    Bachofner M; Blickenstorfer K; Hutmacher J; Wehrle L; Leeners B; Merki-Feld G
    Eur J Contracept Reprod Health Care; 2018 Dec; 23(6):407-414. PubMed ID: 30628516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relative Risk of Cervical Neoplasms Among Copper and Levonorgestrel-Releasing Intrauterine System Users.
    Spotnitz ME; Natarajan K; Ryan PB; Westhoff CL
    Obstet Gynecol; 2020 Feb; 135(2):319-327. PubMed ID: 31923062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
    Heinemann K; Reed S; Moehner S; Minh TD
    Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free-of-charge long-acting reversible contraception: two-year discontinuation, its risk factors, and reasons.
    Saloranta TH; Gyllenberg FK; But A; Gissler M; Laine MK; Heikinheimo O
    Am J Obstet Gynecol; 2020 Dec; 223(6):886.e1-886.e17. PubMed ID: 32562657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
    Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
    Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and efficacy in parous women of a 52-mg levonorgestrel-medicated intrauterine device: a 7-year randomized comparative study with the TCu380A.
    Rowe P; Farley T; Peregoudov A; Piaggio G; Boccard S; Landoulsi S; Meirik O;
    Contraception; 2016 Jun; 93(6):498-506. PubMed ID: 26916172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year continuation of intrauterine devices and contraceptive implants in a mixed-payer setting: a retrospective review.
    Sanders JN; Turok DK; Gawron LM; Law A; Wen L; Lynen R
    Am J Obstet Gynecol; 2017 Jun; 216(6):590.e1-590.e8. PubMed ID: 28188772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bleeding pattern difference between levonorgestrel intrauterine system and copper intrauterine devices inserted immediately post-abortion: a multicenter, prospective, observational cohort study in Chinese women.
    Chen X; Li Q; Wang X; Chen J; Lv W; Shi B; Wang H; Luo J; Li J
    Curr Med Res Opin; 2018 May; 34(5):873-880. PubMed ID: 29298525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detailed analysis of menstrual bleeding patterns after postmenstrual and postabortal insertion of a copper IUD or a levonorgestrel-releasing intrauterine system.
    Suvisaari J; Lähteenmäki P
    Contraception; 1996 Oct; 54(4):201-8. PubMed ID: 8922872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Major differences in the characteristics of users of the copper intrauterine device or levonorgestrel intrauterine system at a clinic in Campinas, Brazil.
    Laporte M; Metelus S; Ali M; Bahamondes L
    Int J Gynaecol Obstet; 2022 Feb; 156(2):240-246. PubMed ID: 33872406
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postplacental placement of intrauterine devices: A randomized clinical trial.
    Laporte M; Marangoni M; Surita F; Juliato CT; Miadaira M; Bahamondes L
    Contraception; 2020 Mar; 101(3):153-158. PubMed ID: 31927027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated disability-adjusted life years averted by long-term provision of long acting contraceptive methods in a Brazilian clinic.
    Bahamondes L; Bottura BF; Bahamondes MV; Gonçalves MP; Correia VM; Espejo-Arce X; Sousa MH; Monteiro I; Fernandes A
    Hum Reprod; 2014 Oct; 29(10):2163-70. PubMed ID: 25085802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Weight variation in users of the levonorgestrel-releasing intrauterine system, of the copper IUD and of medroxyprogesterone acetate in Brazil].
    Yela DA; Monteiro IM; Bahamondes LG; Del Castillo S; Bahamondes MV; Fernandes A
    Rev Assoc Med Bras (1992); 2006; 52(1):32-6. PubMed ID: 16622536
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Complications and continuation of intrauterine device use among commercially insured teenagers.
    Berenson AB; Tan A; Hirth JM; Wilkinson GS
    Obstet Gynecol; 2013 May; 121(5):951-958. PubMed ID: 23635730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expulsion and continuation rates of the 52 mg levonorgestrel intrauterine system in adolescents and adult women.
    Brull E; Machado HC; Bahamondes L; Juliato CRT
    Eur J Contracept Reprod Health Care; 2023 Aug; 28(4):210-215. PubMed ID: 37335234
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preference for and efficacy of oral levonorgestrel for emergency contraception with concomitant placement of a levonorgestrel IUD: a prospective cohort study.
    Turok DK; Sanders JN; Thompson IS; Royer PA; Eggebroten J; Gawron LM
    Contraception; 2016 Jun; 93(6):526-32. PubMed ID: 26944863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.